Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BG505 SOSIP 664 gp140 vaccine adjuvanted - GSK/International AIDS Vaccine Initiative

Next Previous
Drug Profile

BG505 SOSIP 664 gp140 vaccine adjuvanted - GSK/International AIDS Vaccine Initiative

Alternative Names: BG505 SOSIP 664 gp140 adjuvanted vaccine; BG505 SOSIP.664 gp140 adjuvanted; BG505 SOSIP.664 gp140 Vaccine

Latest Information Update: 09 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator International AIDS Vaccine Initiative
  • Developer GSK; International AIDS Vaccine Initiative; Weill Cornell Medical College
  • Class Immunotherapies; Protein vaccines; Recombinant proteins; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 04 Nov 2024 National Institute of Allergy and Infectious Diseases (NIAID) completes a phase I trial for HIV infection (Prevention) in USA (IM) (NCT04177355)
  • 11 Jun 2024 Phase-I development is ongoing in Netherlands (NCT05983874)
  • 28 Dec 2023 BG 505 SOSIP 664 gp140 adjuvanted vaccine is still in phase I trial for HIV-infections (Prevention) in USA (IM) (NCT03699241)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top